ANAB Research and Charts

ANAB - AnaptysBio Inc (Healthcare: Biotechnology)

Projected Earnings Date: 0000-02-29 (Delayed quote data 2026-02-10)

Last 50.24	Change ⇑ +0.29 (+0.58%)	Volume 235,214
	Open 49.72	High 51.37	Low 48.95

8EMA (Daily) 49.34	40EMA (Daily) 46.74	50EMA (Daily) 45.73	STO (Daily) 63.934	MACD Hist (Daily) 0.116
8EMA (Weekly) 47.344	40EMA (Weekly) 35.72	50EMA (Weekly) 33.84	STO (Weekly) 80.405	MACD Hist (Weekly) -0.279


Company Profile
AnaptysBio Inc is clinical-stage biotechnology company. It is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company develops product candidates to address emerging biological targets using its proprietary, antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation. Its product candidates are ANB020, ANB019, and Checkpoint receptor agonist. The entity generates revenue from the collaborative research and development arrangements.

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.